MEDP · Medpace Holdings, Inc.
$528.12
+14.71% last session
End-of-day data · updated 2026-07-24
Market cap
$17B
Enterprise value
$17B
Trailing P/E
38.1
Forward P/E
32.3
Dividend yield
—
Beta
—
Avg volume
0M
Employees
6K
2D change
14.71%
5D change
12.66%
10D change
12.99%
30D change
18.14%
60D change
39.98%
MTD change
11.45%
YTD change
7.86%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MEDP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-24
Latest call per bank · past 12 months
RBC Capital
Outperform$692
+31.0% vs priceJefferies
Hold$515
-2.5% vs priceBarclays
Equal-Weight$450
-14.8% vs priceUBS
Sell$305
-42.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-24 | Mizuho | Maintains | Outperform | $586 → $665 |
| 2026-07-24 | BMO Capital | Maintains | Market Perform | $400 → $600 |
| 2026-07-24 | Truist Securities | Maintains | Hold | $462 → $609 |
| 2026-07-24 | TD Cowen | Maintains | Hold | $419 → $492 |
| 2026-07-24 | RBC Capital | Maintains | Outperform | $484 → $692 |
| 2026-07-24 | Baird | Maintains | Neutral | $547 → $624 |
| 2026-07-13 | Mizuho | Maintains | Outperform | $495 → $586 |
| 2026-07-08 | Baird | Downgrade | Outperform → Neutral | $477 → $547 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 75 — overbought territory; the recent run-up may be due for a pause.
- Price vs 50-day MA: Trading 25.0% above the 50-day MA ($484.64).
- Price vs 200-day MA: Trading 17.4% above the 200-day MA ($516.23).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.66) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($620.59).
MEDP Price Chart
Loading chart for MEDP…
Fundamentals
About Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$213B -1.0% YTD
DHR
Danaher Corporation
$135B -15.6% YTD
IDXX
IDEXX Laboratories, Inc.
$43B -20.3% YTD
A
Agilent Technologies, Inc.
$39B 3.3% YTD
NTRA
Natera, Inc.
$38B 15.5% YTD
WAT
Waters Corporation
$38B 0.7% YTD
IQV
IQVIA Holdings, Inc.
$35B -8.0% YTD
ILMN
Illumina, Inc.
$30B 50.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.